CTIC CTI BioPharma Corp.

0.92
+0.01  (+2%)
Previous Close 0.91
Open 0.92
Price To Book 0.93
Market Cap 53413264
Shares 57,988,562
Volume 121,653
Short Ratio
Av. Daily Volume 378,131

SEC filingsSee all SEC filings

  1. 8-K - Current report 19626004
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19597965
  3. 8-K - Current report 19582124
  4. 8-K - Current report 19557778
  5. 8-K - Current report 19506156

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 9. 2018. Primary endpoint not met.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 2 completion of enrolment announced December 28, 2018, top-line data due 3Q 2019, with Phase 3 to commence 3Q 2019.
Pacritinib - PAC203
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
  2. CTI BioPharma collects $10M payment for former chemotherapy drug
  3. CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
  4. Ex-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissed
  5. CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
  6. CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
  7. CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
  8. As CTI BioPharma restructures, former CEO James Bianco launches startup
  9. The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
  10. CTI BioPharma lays off half of workforce to save cash for lead drug trial
  11. CTI BioPharma Announces Restructuring Plan
  12. CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency
  13. CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
  14. CTI BioPharma: 3Q Earnings Snapshot
  15. CTI BioPharma Reports Third Quarter 2018 Financial Results
  16. CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018
  17. Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?
  18. CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
  19. CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

SEC Filings

  1. 8-K - Current report 19626004
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19597965
  3. 8-K - Current report 19582124
  4. 8-K - Current report 19557778
  5. 8-K - Current report 19506156
  6. 8-K - Current report 181256128
  7. 8-K - Current report 181241073
  8. 8-K - Current report 181233904
  9. 8-K - Current report 181201350
  10. 8-K - Current report 181154176